logo

For the Inventor, By the Inventor

Cambridge, MA, United States of America

Acceleron Pharma Inc.


USPTO Granted Patents = 172

% Expired Patents = 0.58



Forward Citations = 2,229

Loading Chart...
Loading Chart...

61 inventors (with patents filed for the assignee):

goldMedal Ravindra Kumar (119 out of 138 patents)

silverMedal Jasbir S Seehra (84 out of 112 patents)

bronzeMedal John L Knopf (76 out of 87 patents)

4.  Asya Grinberg (52 out of 67 patents)

5.  Dianne S Sako (38 out of 53 patents)

6.  Roselyne Castonguay (34 out of 35 patents)

7.  Robert Scott Pearsall (32 out of 32 patents)

8.  Jonathan Belk (10 out of 21 patents)

9.  Matthew L Sherman (10 out of 13 patents)

10.  Yossi Dagon (9 out of 10 patents)

11.  Kenneth M Attie (8 out of 8 patents)

12.  Gang Li (7 out of 7 patents)

13.  Rajasekhar Naga Venkata Sai Suragani (6 out of 6 patents)

14.  Nathan J Sharkey (6 out of 8 patents)

15.  Naga Venkata Sai Rajasekhar Suragani (6 out of 6 patents)


Core Competencies:
Pulmonary Hypertension
ALK7 Proteins
TGF-Beta Receptor
Anemia Treatments
Myelofibrosis
Muscular Dystrophy
Heterotopic Ossification
Kidney Fibrosis
Erythropoiesis
Sclerotic Disorders
Follistatin Polypeptides
Endoglin Peptides

172 patents:

1. 12678483 - METHODS FOR TREATING PULMONARY DISEASE WITH A LIGAND BINDING DOMAIN OF A TGF-BETA TYPE II RECEPTOR (2026-07-14),
2. 12673998 - ALK7 Binding Proteins and Uses Thereof (2026-07-07),
3. 12583906 - ACTRII PROTEINS AND USE IN TREATING POST-CAPILLARY PULMONARY HYPERTENSION (2026-03-24),
4. 12545736 - ACTRII-BINDING PROTEINS AND USES THEREOF (2026-02-10),
5. 12527839 - TREATMENTS FOR SYSTEMIC SCLEROSIS (2026-01-20),
6. 12421295 - TGF-beta superfamily type I and type II receptor heteromultimers and uses thereof (2025-09-23),
7. 12365736 - ALK7 binding proteins and uses thereof (2025-07-22),
8. 12364736 - Methods for treating heterotopic ossification (2025-07-22),
9. 12343378 - Compositions and methods for treating pulmonary hypertension (2025-07-01),
10. 12258380 - ALK4:actriib heteromultimers and uses thereof (2025-03-25),
11. 12240887 - Variant ActRIIB proteins and uses thereof (2025-03-04),
12. 12195519 - Transforming growth factor-beta (TGF-beta) receptor type II fusion polypeptides (2025-01-14),
13. 12194076 - Methods and compositions for treating myelofibrosis (2025-01-14),
14. 12168683 - Binders of TGFβ-superfamily ligands and uses thereof (2024-12-17),
15. 12145970 - Twisted gastrulation polypeptides and uses thereof (2024-11-19),
Acceleron Pharma Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutics for serious and rare diseases. They strive to transform the lives of patients by leveraging their deep understanding of biology, scientific innovation, and translational expertise. With a commitment to advancing novel therapies, Acceleron aims to improve outcomes and quality of life for patients worldwide.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 15 2026

Acceleron Pharma Inc.
172 Patents

#16 in Cambridge, MA

#128 in Massachusetts

#2,326 in US

#4,809 in the World

Cambridge, MA (US)
Cambridge, MA, United States of America

Acceleron Pharma Inc.

Forward Citations = 2,229

61 inventors:

goldMedal Ravindra Kumar (119 out of 138 patents)

silverMedal Jasbir S Seehra (84 out of 112 patents)

bronzeMedal John L Knopf (76 out of 87 patents)

4.  Asya Grinberg (52 out of 67 patents)

5.  Dianne S Sako (38 out of 53 patents)

Please report any incorrect information to [email protected]
Loading…